Cargando…

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status

INTRODUCTION: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer's disease dementia (AD) from other neurodegenerative processes. METHODS: CSF biom...

Descripción completa

Detalles Bibliográficos
Autores principales: Campbell, Michelle R., Ashrafzadeh‐Kian, Susan, Petersen, Ronald C., Mielke, Michelle M., Syrjanen, Jeremy A., van Harten, Argonde C., Lowe, Val J., Jack, Clifford R., Bornhorst, Joshua A., Algeciras‐Schimnich, Alicia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129859/
https://www.ncbi.nlm.nih.gov/pubmed/34027020
http://dx.doi.org/10.1002/dad2.12190
_version_ 1783694392697028608
author Campbell, Michelle R.
Ashrafzadeh‐Kian, Susan
Petersen, Ronald C.
Mielke, Michelle M.
Syrjanen, Jeremy A.
van Harten, Argonde C.
Lowe, Val J.
Jack, Clifford R.
Bornhorst, Joshua A.
Algeciras‐Schimnich, Alicia
author_facet Campbell, Michelle R.
Ashrafzadeh‐Kian, Susan
Petersen, Ronald C.
Mielke, Michelle M.
Syrjanen, Jeremy A.
van Harten, Argonde C.
Lowe, Val J.
Jack, Clifford R.
Bornhorst, Joshua A.
Algeciras‐Schimnich, Alicia
author_sort Campbell, Michelle R.
collection PubMed
description INTRODUCTION: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer's disease dementia (AD) from other neurodegenerative processes. METHODS: CSF biomarkers were measured in 150 participants from the Mayo Clinic Study of Aging and the Alzheimer's Disease Research Center. P‐tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) and Aβ42/40 (Fujirebio LUMIPULSE) ratios were compared to one another and to amyloid positron emission tomography (PET) classification. RESULTS: Strong correlation was observed between LUMIPULSE p‐tau/Aβ42 and Aβ42/40, as well as Elecsys and LUMIPULSE p‐tau/Aβ42 and Aβ42/40 (Spearman's ρ = –0.827, –0.858, and 0.960, respectively). Concordance between LUMIPULSE p‐tau/Aβ42 and Aβ42/40 was 96% and between Elecsys p‐tau/Aβ42 and both LUMIPULSE ratios was 97%. All ratios had > 94% overall, positive, and negative percent agreement with amyloid PET classification. DISCUSSION: These data suggest that p‐tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology.
format Online
Article
Text
id pubmed-8129859
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81298592021-05-21 P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status Campbell, Michelle R. Ashrafzadeh‐Kian, Susan Petersen, Ronald C. Mielke, Michelle M. Syrjanen, Jeremy A. van Harten, Argonde C. Lowe, Val J. Jack, Clifford R. Bornhorst, Joshua A. Algeciras‐Schimnich, Alicia Alzheimers Dement (Amst) Cerebrospinal Fluid Biomarkers INTRODUCTION: Measurement of amyloid beta (Aβ40 and Aβ42) and tau (phosphorylated tau [p‐tau] and total tau [t‐tau]) in cerebrospinal fluid (CSF) can be utilized to differentiate clinical and preclinical Alzheimer's disease dementia (AD) from other neurodegenerative processes. METHODS: CSF biomarkers were measured in 150 participants from the Mayo Clinic Study of Aging and the Alzheimer's Disease Research Center. P‐tau/Aβ42 (Roche Elecsys, Fujirebio LUMIPULSE) and Aβ42/40 (Fujirebio LUMIPULSE) ratios were compared to one another and to amyloid positron emission tomography (PET) classification. RESULTS: Strong correlation was observed between LUMIPULSE p‐tau/Aβ42 and Aβ42/40, as well as Elecsys and LUMIPULSE p‐tau/Aβ42 and Aβ42/40 (Spearman's ρ = –0.827, –0.858, and 0.960, respectively). Concordance between LUMIPULSE p‐tau/Aβ42 and Aβ42/40 was 96% and between Elecsys p‐tau/Aβ42 and both LUMIPULSE ratios was 97%. All ratios had > 94% overall, positive, and negative percent agreement with amyloid PET classification. DISCUSSION: These data suggest that p‐tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology. John Wiley and Sons Inc. 2021-05-18 /pmc/articles/PMC8129859/ /pubmed/34027020 http://dx.doi.org/10.1002/dad2.12190 Text en © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Cerebrospinal Fluid Biomarkers
Campbell, Michelle R.
Ashrafzadeh‐Kian, Susan
Petersen, Ronald C.
Mielke, Michelle M.
Syrjanen, Jeremy A.
van Harten, Argonde C.
Lowe, Val J.
Jack, Clifford R.
Bornhorst, Joshua A.
Algeciras‐Schimnich, Alicia
P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
title P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
title_full P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
title_fullStr P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
title_full_unstemmed P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
title_short P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
title_sort p‐tau/aβ42 and aβ42/40 ratios in csf are equally predictive of amyloid pet status
topic Cerebrospinal Fluid Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129859/
https://www.ncbi.nlm.nih.gov/pubmed/34027020
http://dx.doi.org/10.1002/dad2.12190
work_keys_str_mv AT campbellmicheller ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT ashrafzadehkiansusan ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT petersenronaldc ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT mielkemichellem ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT syrjanenjeremya ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT vanhartenargondec ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT lowevalj ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT jackcliffordr ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT bornhorstjoshuaa ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus
AT algecirasschimnichalicia ptauab42andab4240ratiosincsfareequallypredictiveofamyloidpetstatus